Neuropathic pain
Conditions
Interventions
Comparison of spinal TSPO-PET accumulation between the patients with neuropathic pain and normal volunteers. Comparison between spinal TSPO-PET accumulation and plasma 24OHC or plasma BDNF among 2 gro
Sponsors
Osaka University Hospital
SHIONOGI &
CO., LTD.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged from 20 to 84 years-old (n=15). Normal volunteers aged from 20 to 40 years-old (n=5). 2. Patients with the symptom of definite neuropathic pain or probable neuropathic pain who are diagnosed by the algorithm of the International Association for the Study of Pain. 3. Patients who can provide written informed consent prior to their participation.
Exclusion criteria
Exclusion criteria: <Exclusion criteria for patients> 1. Pregnant women, nursing mothers and the women who may be pregnant. 2. The patients with the severe psycho-neurologic disease (major depression or schizophrenia). 3. Patients with a history of the severe injury with sliding symptoms due to a vertebral fracture and the backbone trauma within six months. 4. Patients with the discectomy, nerve cauterization, and vertebra plasty within six months. 5. Algetic patients due to articular rheumatism, ankylosing spondylitis, and spinal inflammation or tumor. 6. Patients who are unsolved accident compensation about the pain and financial mediation/suit. 7. Patients with a history of HIV. 8. Patients who are participating into other clinical trials. 9. Patients who are judged to be inadequate as subjects by the principal investigator. <Exclusion criteria for normal volunteers> 1. Pregnant women, nursing mothers and the women who may be pregnant. 2. Subjects with the severe psycho-neurologic disease (major depression or schizophrenia). 3. Subjects who suffer from hypertention, hyperlipidemia, vascular disease, and/or cardiac disease. 4. The subjects who have symptoms of pain. 5. Subjects who have claustrophobia. 6. Subjects who suffer from malignant tumors. 7. Subjects who have allergy. 8. Subjects who have smoking behavior and alcohol indulgence. 9. Subjects with a history of HIV. 10. Subjects who are participating into other clinical trials. 11. Subjects who are judged to be inadequate as subjects by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Spinal accumulations of TSPO-PET (C-11 DPA-713 PET) in the patients with neuropathic pain, which are evaluated within 4 weeks after entry. Relationships between spinal accumulation of TSPO-PET and plasma 24OHC or plasma BDNF. | — |
Countries
Japan
Contacts
Public ContactEku Shimosegawa
Osaka University Graduate School of Medicine Department of Molecular Imaging in Medicine
Outcome results
None listed